Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis

Digestive Diseases and Sciences

Volumn 59, Issue 4, 2014, Pages 807-813

  Huang, Kuang Wei ^a,c   Leu, Hsin Bang ^a,b   Luo, Jiing Chyuan ^a,b   Chan, Wan Leong ^a,b   Hou, Ming Chih ^a,b   Lin, Han Chieh ^a,b   Lee, Fa Yauh ^a,b   Kuan, Yi Chun ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic kidney disease (CKD); End stage renal disease (ESRD); Hemodialysis (HD); Peptic ulcer bleeding (PUB); Peritoneal dialysis (PD)

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; END STAGE RENAL DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMODIALYSIS; HOSPITALIZATION; HUMAN; ICD-9-CM; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; PEPTIC ULCER BLEEDING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; COMORBIDITY; DIABETIC NEPHROPATHIES; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; PERITONEAL DIALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TAIWAN;

EID: 84897385858     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2973-6     Document Type: Article

References (39)

1. US Renal Data System (USRDS). Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
2. Garrow D, Delegge MH. Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci. 2010;55:66-72. doi:10.1007/s10620-008-0708-x.
3. Kong SX, Hatoum HT, Zhao SZ, Agrawal NM, Geis SG. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care. 1998;4:399-409. (Pubitemid 28350796)
4. Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010;123:e2.
5. Xia HH, Phung N, Altiparmak E, Berry A, Matheson M, Talley NJ. Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998. Dig Dis Sci. 2001;46:2716-2723. doi:10.1023/A:1012731614075. (Pubitemid 33141044)
6. Xia B, Xia HH, Ma CW, et al. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physi-cian- referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther. 2005;22:243-249. (Pubitemid 41153067)
7. Luo JC, Leu HB, Huang KW, et al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ. 2011;183:E1345-E1351.
8. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Longterm peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011;60:1038-1042.
9. Huang KW, Luo JC, Leu HB, et al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment Pharmacol Ther. 2012;35:796-802.
10. Luo JC, Leu HB, Hou MC, et al. Non-peptic ulcer, non-variceal gastrointestinal bleeding in hemodialysis patients. Am J Med. 2013;126:264.e25-264.e32.
11. Luo JC, Leu HB, Hou MC, et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2012;36:542-550.
12. Doherty CC, O'Connor FA, Buchanan KD, Sloan JM, Douglas JF, McGeown MG. Treatment of peptic ulcer in renal failure. Proc Eur Dial Transplant Assoc. 1977;14:386-395.
13. Kang JY, Ho KY, Yeoh KG, et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol. 1999;14:771-778. (Pubitemid 29426409)
14. Tseng GY, Lin HJ, Fang CT, et al. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther. 2007;26:925-933.
15. Chen YT, Yang WC, Lin CC, Ng YY, Chen JY, Li SY. Comparison of peptic ulcer disease risk between peritoneal and hemodialysis patients. Am J Nephrol. 2010;32:212-218.
16. Lee SW, Song JH, Kim GA, Yang HJ, Lee KJ, Kim MJ. Effect of dialysis modalities on gastric myoelectrical activity in end-stage renal disease patients. Am J Kidney Dis. 2000;36:566-573.
17. Kerrigan DD, Read NW, Houghton LA, Taylor ME, Johnson AG. Disturbed gastroduodenal motility in patients with active and healed duodenal ulceration. Gastroenterology. 1991;100:892-900.
18. Kamiya T, Kobayashi Y, Hirako M, et al. Gastric motility in patients with recurrent gastric ulcers. J Smooth Muscle Res. 2002;38:1-9. (Pubitemid 34988300)
19. Borazan A, Cavdar Z, Saglam F. The effect of renal replacement therapies on serum gastrointestinal system hormones. Ren Fail. 2007;29:1019-1023. (Pubitemid 350232891)
20. Aguilera A, Bajo MA, Espinoza M, et al. Gastrointestinal and pancreatic function in peritoneal dialysis patients: their relationship with malnutrition and peritoneal membrane abnormalities. Am J Kidney Dis. 2003;42:787-796. (Pubitemid 37187380)
21. Fourmy D, Gigoux V, Reubi JC. Gastrin in gastrointestinal diseases. Gastroenterology. 2011;141:e1-e3.
22. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW, Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis. 2004;43:891-899. (Pubitemid 38529627)
23. Stack AG. Determinants of modality selection among incident US dialysis patients: results from a national study. J Am Soc Nephrol. 2002;13:1279-1287. (Pubitemid 34441409)
24. Kendix M. Dialysis modality selection among patients attending freestanding dialysis facilities. Health Care Financ Rev. 1997;18:3-21. (Pubitemid 27516397)
25. Liang CH, Yang CY, Lu KC, et al. Factors affecting peritoneal dialysis selection in Taiwanese patients with chronic kidney disease. Int Nurs Rev. 2011;58:463-469.
26. Tam P. Peritoneal dialysis and preservation of residual renal function. Perit Dial Int. 2009;29:S108-S110.
27. Radulescu D, Ferechide D. The importance of residual renal function in chronic dialysed patients. J Med Life. 2009;2:199-206.
28. Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212-1218. (Pubitemid 36637976)
29. Marques de Mattos A, Marino LV, Ovidio PP, Jordão AA, Almeida CC, Chiarello PG. Protein oxidative stress and dyslipidemia in dialysis patients. Ther Apher Dial. 2012;16:68-74.
30. Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol. 2003;35:393-397. (Pubitemid 39127558)
31. Kang JM, Kim N, Kim JH, et al. Effect of aging on gastric mucosal defense mechanisms: ROS, apoptosis, angiogenesis, and sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1147-G1153.
32. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2007;50:602-611. (Pubitemid 47444460)
33. Jankovic SM, Aleksic J, Rakovic S, et al. Non-steroidal antiinflammatory drugs and risk of gastro-intestinal bleeding among patients on hemodialysis. J Nephrol. 2009;22:502-507.
34. Steinhauer HB, Gunter B, Schollmeyer P. Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Invest. 1985;15:1-5. (Pubitemid 15126845)
35. Luo JC, Shin VY, Liu ES, et al. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther. 2003;307:692-698. (Pubitemid 37310685)
36. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet. 2002;359:14-22. (Pubitemid 34119190)
37. Shousha S, Arnaout AH, Abbas SH, Parkins RA. Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol. 1990;43:397-399. (Pubitemid 20154202)
38. Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009;75:96-103.
39. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997;24:2-17. (Pubitemid 27051940)